Elixir Medical: A medical devices company creating next-generation treatments for heart and vascular diseases

Heart disease is the world's number one killer, claiming close to 20 million lives a year. One of the biggest culprits is coronary artery disease, where fatty deposits build up inside the arteries that feed the heart, causing them to narrow or clog. That restricts blood flow, and with it the oxygen the heart needs, which can lead to chest pain or a heart attack. 

For decades, the standard answer has been the stent: a tiny mesh tube that props the vessel open and holds it there for good. Stents save lives, but they are a permanent fix inside a body that never stops moving, and a share of patients keep facing complications year after year. 

That is the gap Elixir Medical set out to close, rethinking how heart and vascular disease is treated and building a new generation of medical devices designed to work with the body rather than simply holding it open. 

Who are Elixir Medical? 

Founded in 2005 and based in Milpitas, California, Elixir is led by its founder and CEO Motasim Sirhan. An engineer by training who had already built and sold the vascular company Avantec, Sirhan kept returning to one stubborn fact: no matter how advanced stents became, they rarely improved outcomes much beyond the first year, with complications tied to stent failure adding up at a steady 2 to 3 percent every year after that. 

The mission follows straight from that insight. Rather than engineer a slightly better version of the same device, Elixir wants to move, in Sirhan's words, "beyond the limitations of metallic drug-eluting stents," changing how heart and vascular disease is treated so that results hold up long after the procedure. A place on Fast Company's list of the World's Most Innovative Companies of 2025 suggests the field is taking notice. 

Their technology: devices that adapt to the body 

Elixir's portfolio focuses on coronary and peripheral artery disease, with devices that take a smarter approach to a familiar problem. 

The flagship is the DynamX Coronary Bioadaptor. Where a traditional stent stays locked in place for good, the bioadaptor does its job and then eases off. Once it has restored blood flow, an outer element unlocks around six months later, freeing the artery to flex, pulse and move naturally again while still lending support where it is needed.  

In long-term trial data, DynamX cut a key measure of treatment failure by around two thirds compared with a leading conventional stent. It is now approved in Europe and Japan, and holds Breakthrough Device Designation from the US Food and Drug Administration, a fast-track status for technologies with real potential to improve care. 

A second device, the LithiX Hertz Contact Intravascular Lithotripsy System, takes on a different problem. Many patients have arteries stiffened by calcium, which makes them hard to treat. Lithotripsy breaks up those calcium deposits, and LithiX does it with tiny metal hemispheres on a balloon that crack the hardened plaque under gentle pressure, without the external energy source rival systems rely on. It has been approved in Europe since 2025. 

Between them, DynamX and LithiX give Elixir two commercially approved devices, both carrying European CE Mark clearance and with DynamX now approved in Japan as well. They build on earlier drug-eluting stent and scaffold systems from the company's first two decades, while a third platform, a site-specific antithrombotic therapy, is still in development. 

Potential impact 

The potential reach is enormous. Around 7 million coronary procedures are performed worldwide every year, the large majority involving a stent, and roughly a third involve the kind of hardened, calcified arteries that a device like LithiX is built for. At that scale, even small improvements add up to a great many lives. For the clinicians doing the work, newer devices also mean more tools to reach for when a standard stent is not the right answer. 

What stands out about Elixir is not just the devices but the thinking behind them. By designing technology that helps arteries heal and move naturally, rather than only holding them open, the company is widening the options physicians have for their most complex and high-risk cases. For patients, that can mean fewer complications down the line, and for the field, proof that even well-established treatments have meaningful ground to gain. 

Meet takes pride in helping life sciences organizations build teams that contribute to life-changing medicines and medical devices. From clinical-stage scale-ups to well-established companies, we help place the people behind the advancements that improve global health outcomes. 

If you're working in the medical devices space and looking for your next role, or to expand your team, feel free to contact us today. Our industry experts will be able to get the process started for you.